In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione

International Journal of Antimicrobial Agents

Volumn 48, Issue 3, 2016, Pages 328-330

  Papp, John R ^a   Lawrence, Kenneth ^b   Sharpe, Samera ^a   Mueller, John ^b   Kirkcaldy, Robert D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Entasis Therapeutics   (United States)

Author keywords

Antimicrobial susceptibility; Gonorrhoea; Neisseria gonorrhoeae; Novel drug

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; TETRACYCLINE; ZOLIFLODACIN; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; SPIRO COMPOUND;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; GONORRHEA; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT NEISSERIA GONORRHOEAE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; URETHRITIS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; UNITED STATES;

ANTI-BACTERIAL AGENTS; BARBITURATES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; SPIRO COMPOUNDS; UNITED STATES; URETHRITIS;

EID: 84984815325     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.05.018     Document Type: Article

References (20)

1. [1] World Health Organization, Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012, WHO, Geneva, Switzerland.
2. [2] US Centers for Disease Control and Prevention, Antibiotic resistance threats in the United States, 2013. 2013, CDC, US Department of Health and Human Services, Atlanta, GA.
3. [3] Unemo, M., Shafer, W.M., Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27 (2014), 587–613.
4. [4] US Centers for Disease Control and Prevention, Sexually transmitted diseases treatment guidelines. 2015, CDC, US Department of Health and Human Services, Washington, DC.
5. [5] Public Health Agency of Canada, Canadian guidelines on sexually transmitted infections: gonococcal infections. 2013, Public Health Agency of Canada, Ottawa, ON, Canada.
6. [6] British Association for Sexual Health and HIV, BASHH clinical effectiveness group guidelines. 2015, BASHH, Macclesfield, UK http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx accessed 23.05.16.
7. [7] US Centers for Disease Control and Prevention, Gonococcal Isolate Surveillance Project (GISP). 2015, CDC, Atlanta, GA http://www.cdc.gov/std/gisp/default.htm accessed 23.05.16.
8. [8] Ison, C.A., Town, K., Obi, C., Chisholm, S., Hughes, G., Livermore, D.M., et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis 13 (2013), 762–768.
9. [9] Centers for Disease Control and Prevention (CDC), Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56 (2007), 332–336.
10. [10] Belland, R.J., Morrison, S.G., Ison, C., Huang, W.M., Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 14 (1994), 371–380.
11. [11] Basarab, G.S., Kern, G.H., McNulty, J., Mueller, J.P., Lawrence, K., Vishwanathan, K., et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci Rep 5 (2015), 1–13.
12. [12] Alm, R.A., Lahiri, S.D., Kutschke, A., Otterson, L.G., McLaughlin, R.E., Whiteaker, J.D., et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59 (2015), 1478–1486.
13. [13] Kern, G., Palmer, T., Ehmann, D.E., Shapiro, A.B., Andrews, B., Basarab, G.S., et al. Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem 290 (2015), 20984–20994.
14. [14] US Centers for Disease Control and Prevention, Gonococcal Isolate Surveillance Project (GISP) protocol. http://www.cdc.gov/std/gisp/gisp-protocol-oct-2014.pdf, 2015 accessed 23.05.16.
15. [15] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. 2015, CLSI, Wayne, PA Document M100-S25.
16. [16] World Health Organization, Global incidence and prevalence of selected curable sexually transmitted infections—2008. 2012, WHO, Geneva, Switzerland.
17. [17] US Centers for Disease Control and Prevention, Gonorrhea statistics. 2015, Atlanta, GA, CDC http://www.cdc.gov/std/gonorrhea/stats.htm accessed 23.05.16.
18. [18] Kirkcaldy, R.D., Hook, I.I.I.E.W., Soge, O., del Rio, C., Kubin, G., Zenilman, J.M., et al. Changing trends in Neisseria gonorrhoeae susceptibility to cephalosporins and its implications for gonorrhea treatment: sentinel surveillance data from the Gonococcal Isolate Surveillance Project, United States, 2006–June 2014. JAMA 314 (2015), 1869–1871.
19. [19] Unemo, M., Ringlander, J., Wiggins, C., Fredlund, H., Jacobsson, S., Cole, M., High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother 59 (2015), 5220–5225.
20. [20] Foerster, S., Golparian, D., Jacobsson, S., Hathaway, L.J., Low, N., Shafer, W.M., et al. Genetic resistance determinants, in vitro time–kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol 6 (2015), 1–13.